FLAURA

NCT02296125 📎

Regimen

Experimental
osimertinib
Control
gefitinib or erlotinib

Population

Advanced EGFR-mut (del19/L858R) NSCLC, chemo-naive

Key finding

mPFS 18.9 vs 10.2 mo, HR 0.46 (0.37-0.57); OS update mOS 38.6 vs 31.8 mo HR 0.80

Source: PMID 29151359

Timeline

  • Enrollment start: 2014-12-03 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.200)
  • CSCO NSCLC 2025 ⚠️ OCR source